MXCT Share Price Performance
UK£1.52
-1.14 (-42.86%)
68.8% undervalued intrinsic discount
UK£4.87
Fair Value
Price UK£1.52
AnalystConsensusTarget UK£4.87
Fair ValueUK£4.87
Share Pricen/a
MaxCyte, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
MXCT Community Narratives
AN
Fair Value UK£4.87 68.8% undervalued intrinsic discount
SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects
Key Takeaways Acquisition of SeQure Dx and SPL portfolio expansion could drive future revenue growth through improved offerings and new clinical progressions. Strategic focus on efficiency and high-growth areas may enhance net margins and long-term profitability amid expected market growth in cell and gene therapy.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
UK£4.87
68.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
17.54% p.a.
Profit Margin
7.9%
Future PE
179.6x
Share price in 2028
UK£6.04
Recently Updated Narratives
AN
SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects
Fair Value: UK£4.87 68.8% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MaxCyte, Inc. Key Details
About MXCT
- Founded
- 1998
- Employees
- 114
- CEO
- WebsiteView website
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
